- cafead May 11, 2021 at 10:32: PM
via AbbVie has inked a series of patent settlements with biosimilar makers allowing U.S. copycat launches to the world's bestselling medicine in 2023. With the first Humira biosim launches a little under 2 years away, Alvotech is hoping to find another route to the market.
Alvotech Tuesday morning said it had filed a federal lawsuit against AbbVie seeking to end the pharma juggernaut's "wrongful monopoly" on the world's best-selling drug.
article source
Alvotech Tuesday morning said it had filed a federal lawsuit against AbbVie seeking to end the pharma juggernaut's "wrongful monopoly" on the world's best-selling drug.
article source